|
Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report: Incyte Corp (INCY)
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:20122008
Several insiders at Incyte Corp (INCY) have reported buying more than
$3.47M today as the stock was trading near its 52-week low:
- Baker Brothers Life Sciences Capital (gp), LLC, Director: reported
buying $2.58M
- Baker / Tisch Capital (gp), LLC, Director: reported buying $17.73K
- 14159 Capital (gp), LLC, Director: reported buying $70.41K
- Baker Bros. Capital (gp), LLC, Director: reported buying $6.73K
- Baker Biotech Capital (gp), LLC, Director: reported buying $796.55K
Over the last four weeks insiders at Incyte Corp (INCY) have bought
more than $3.55M:
- Chardonnet Laurent, : bought $21.68K increasing total holdings by
3200%
- Hastings David C, Chief Financial Officer: bought $9.44K increasing
total holdings by 160%
- Schreck Patricia A, EVP, General Counsel: bought $6.10K increasing
total holdings by 125%
- Friedman Paul A, Chief Executive Officer: bought $33.15K increasing
total holdings by 6%
- Metcalf Brian W, Chief Drug Discovery Scientist: bought $10.95K
increasing total holdings by 11%
- 14159 Capital (gp), LLC, Director: bought $70.41K increasing total
holdings by 7%
- Baker Brothers Life Sciences Capital (gp), LLC, Director: bought
$2.58M increasing total holdings by 13%
- Baker / Tisch Capital (gp), LLC, Director: bought $17.73K increasing
total holdings by 4%
- Baker Bros. Capital (gp), LLC, Director: bought $6.73K increasing
total holdings by < 1%
- Baker Biotech Capital (gp), LLC, Director: bought $796.55K increasing
total holdings by 7%
For a current, real-time summary of INCY insider activity, visit
http://www.form4oracle.com/company?cik=0000879169&ticker=INCY
About Form4Oracle
Form4Oracle, LLC specializes in distributing insider trading
information published by the SEC, making it accessible and actionable
for all types of investors. To learn more about how tracking insider
trading activity can improve your investment returns, visit
http://www.form4oracle.com.
About Incyte Corp
Incyte Corporation operates as a drug discovery and development
company, which focuses on developing proprietary small molecule drugs
to treat human immunodeficiency virus (HIV), diabetes, oncology, and
inflammation diseases. The company?s products include INCB18424 (Oral),
which is in Phase IIa clinical trials for the treatment of
myelofibrosis, rheumatoid arthritis, refractory prostate cancer, and
multiple myeloma, as well as for the treatment of psoriasis in a Phase
I clinical trial; INCB18424 (Topical), which is in a Phase IIa clinical
trial for the treatment of Psoriasis; and INCB28050, a preclinical
stage drug for the treatment of rheumatoid arthritis. Its products also
include INCB13739, which is in a Phase IIa clinical trial for the
treatment of Type 2 Diabetes; and INCB20817, which is in a Phase I
clinical trials for the treatment of Type 2 Diabetes. In addition, the
company?s products include INCB19602 in Phase I clinical trial for the
treatment of Type 2 Diabetes; INCB9471 in Phase II clinical trial for
the treatment of HIV; INCB15050 in Phase I clinical trial for the
treatment of HIV; INCB7839 in Phase IIa clinical trial for the
treatment of solid tumors, and Phase II clinical trial for the
treatment of breast cancer; and INCB8696 in Phase I clinical trial for
the treatment of multiple sclerosis. Further, its pre-clinical stage
products involves in the treatment of oncology disease. The company has
a collaborative research and license agreement with Pfizer, Inc. for
the pursuit of its CCR2 antagonist program. It offers its products in
the United States, Canada, Germany, Sweden, and the United Kingdom.
Incyte Corporation was founded in 1991 and is headquartered in
Wilmington, Delaware.
--------------------------------------------
The companies referenced in this report have not approved the
statements made in this report. This report contains statements that
imply risks and uncertainties. This material is for informational
reporting purposes only and should not be construed as an offer or
solicitation of an offer to buy or sell securities. Form4Oracle is not
a licensed broker, broker dealer, market maker, investment banker,
investment adviser, analyst or underwriter and is not compensated in
this regard.
Please consult your broker to understand investing benefits and risks
and prior to purchasing any securities mentioned herein.
CONTACT: Kimberly Sutton, on behalf of Form4Oracle
e-mail: kimberly@form4oracle.com
Tel: +1 312 315 5077
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ InfoTech Spotlight's Homepage ]
|
